Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with devastating effects. The greatest risk factor to develop AD is age. Today, only symptomatic therapies are available. Additionally, AD can be diagnosed with certainty only post mortem, whereas the diagnosis “probable AD” can be established earliest when severe clinical symptoms appear. Specific neuropathological changes like neurofibrillary tangles and amyloid plaques define AD. Amyloid plaques are mainly composed of the amyloid-βpeptide (Aβ). Several lines of evidence suggest that the progressive concentration and subsequent aggregation and accumulation of Aβplay a fundamental role in the disease progress. Therefore, substances which bind to Aβ and influence aggregation thereof are of great interest. An enormous number of organic substances for therapeutic purposes are described. This review focuses on peptides developed for diagnosis and therapy of AD and discusses the pre- and disadvantages of peptide drugs.
Keywords: Alzheimer's disease, amyloid-β, therapy, peptides, diagnosis, neurodegenerative, symptomatic, dementia, protofibrils, diffusible ligands
Current Pharmaceutical Design
Title: Peptides for Therapy and Diagnosis of Alzheimer's Disease
Volume: 18 Issue: 6
Author(s): Susanne Aileen Funke and Dieter Willbold
Affiliation:
Keywords: Alzheimer's disease, amyloid-β, therapy, peptides, diagnosis, neurodegenerative, symptomatic, dementia, protofibrils, diffusible ligands
Abstract: Alzheimer's disease (AD) is a progressive neurodegenerative disorder with devastating effects. The greatest risk factor to develop AD is age. Today, only symptomatic therapies are available. Additionally, AD can be diagnosed with certainty only post mortem, whereas the diagnosis “probable AD” can be established earliest when severe clinical symptoms appear. Specific neuropathological changes like neurofibrillary tangles and amyloid plaques define AD. Amyloid plaques are mainly composed of the amyloid-βpeptide (Aβ). Several lines of evidence suggest that the progressive concentration and subsequent aggregation and accumulation of Aβplay a fundamental role in the disease progress. Therefore, substances which bind to Aβ and influence aggregation thereof are of great interest. An enormous number of organic substances for therapeutic purposes are described. This review focuses on peptides developed for diagnosis and therapy of AD and discusses the pre- and disadvantages of peptide drugs.
Export Options
About this article
Cite this article as:
Aileen Funke Susanne and Willbold Dieter, Peptides for Therapy and Diagnosis of Alzheimer's Disease, Current Pharmaceutical Design 2012; 18 (6) . https://dx.doi.org/10.2174/138161212799277752
DOI https://dx.doi.org/10.2174/138161212799277752 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Retinoic Acid Metabolism and Mechanism of Action: A Review
Current Drug Metabolism Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design Editorial [Hot Topic:Treatment of Neuroblastoma: From Cellular to Molecular Therapy (Executive Editor: Gian Paolo Tonini)]
Current Pharmaceutical Design Targeting the Atypical Chemokine Receptor ACKR3/CXCR7: Phase 1 - Phage Display Peptide Identification and Characterization
Current Topics in Medicinal Chemistry Electrochemical DNA Biosensors in Drug Analysis
Current Pharmaceutical Analysis Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism
Current Pharmaceutical Design Biocompatible Micelles Based on Squalene Portions Linked to PEGylated Polyaspartamide as Potential Colloidal Drug Carriers
Current Nanoscience Induction of Cellular Oxidative Stress by the β-amyloid Peptide Involved in Alzheimers disease
Protein & Peptide Letters Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era
Current Molecular Pharmacology The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice
Current Molecular Medicine Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Targets for Anticancer Drug Discovery
Current Drug Targets Pluripotent Stem Cell-Derived Somatic Stem Cells as Tool to Study the Role of MicroRNAs in Early Human Neural Development
Current Molecular Medicine Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Advances in Molecular Image-Guided Cancer Radionuclide Therapy
Current Drug Targets Preparation and in-vitro Transfection Efficiency Evaluation of Modified Cationic Liposome-polyethyleneimine-plasmid Nanocomplexes as a Novel Gene Carrier
Current Drug Delivery Interaction of Endocannabinoid Receptors with Biological Membranes
Current Medicinal Chemistry Overview of microRNA Target Analysis Tools
Current Bioinformatics Cancer Immunotherapy: Battling Tumors with Gene Vaccines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents